Sie suchten nach: immunization (Englisch - Maltesisch)

immunization
tilqim

immunization and schedule
tilqim u l-skeda

incomplete primary immunization (adults)
immunizzazzjoni primarja mhux kompleta (adulti)

after 0.25 ml dose primary immunization
wara 0.25 ml doża tal- immunizzazzjoni primarja

booster following recommended primary immunization (2x6 mcg)
booster wara l- immunizzazzjoni primarja rrakkomandata (2x6 mcg)

second dose following incomplete primary immunization (1x6 mcg)
it-tieni doża wara l- immunizzazzjoni primarja mhux kompluta (1x6 mcg)

immunological medicinal products used in public health immunization programmes,
prodotti mediċinali immunoloġiċi wżati fi programmi ta' immunizzazzjoni tas-saħħa pubblika,

zostavax is indicated for immunization of individuals 50 years of age or older.
zostavax huwa indikat għall- immunizzazzjoni ta 'individwi ta' 50 sena jew aktar.

immunization shall be postponed in patients with febrile illness or acute infection.
it-tilqima għandha tiġi posposta f’pazjenti li jkollhom mard bid-deni jew infezzjoni akuta.

primary immunization should be completed at least one week prior to potential exposure to jev.
it-tilqima primarja għandha ssir mill-anqas ġimgħa qabel l-esponiment potenzjali għall-jev.

unless the pregnant workers are proved to be adequately protected against such agents by immunization.
kemm-il darba m'hemmx prova li l-ħaddiema tqal huma protetti kif xieraq kontra dan l-aġent permezz ta' l-immuniżżazzjoni.

if the primary immunization of two injections is not completed, full protection against the disease might not be achieved.
jekk l-immunizzazzjoni primarja ta’ żewġ injezzjonijiet ma tkunx kompluta, għandu mnejn li l-protezzjon sħiħa kontra l-marda ma tingħatax.

prior to initiating soliris therapy, it is recommended that pnh patients should receive immunizations according to current immunization guidelines.
tilqim qabel ma tinbeda terapija b' soliris, huwa rakkomandat li l- pazjenti pnh jirċievu tilqimiet skond il- linji gwida attwali dwar it- tilqim.

for the active immunization of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.
għall-immunita` attiva fit-tiġieġ biex tipprovdi immunita` passiva kontra l- enterite’nekrotika lill- flieles tagħhom, waqt il-perjodu tat-tqegħied il-bajd.

for the active immunization of leishmania negative dogs from 6 months of age to reduce the risk to develop an active infection and clinical disease after contact with leishmania infantum.
għat-tilqim attiv ta’ klieb negattivi għal leishmania li għandhom minn 6 xhur ’il fuq sabiex jitnaqqas ir- riskju li jiżviluppaw infezzjoni attiva u mard kliniku wara li jieħdu leishmania infantum.

the safety of immunization with live viral vaccines, following mabthera therapy has not been studied for nhl and cll patients and vaccination with live virus vaccines is not recommended.
is- sigurtà ta ’ tilqim b’ vaċċini virali ħajjin, wara terapija b’ mabthera ma ġietx studjata għall- pazjenti b’ nhl u cll u tilqim b’ vaċċini virali ħajjin mhux irrakkomandata.

a second booster should therefore be given 10 years after the first booster dose, administered 1 year after the primary immunization, prior to potential exposure to jev.
għaldaqstant it-tieni doża booster għandha tingħata 10 snin wara l-ewwel doża booster, mogħtija sena wara l- immunizzazzjoni primarja, qabel l-esponiment potenzjali għal jev.

therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 to 6 weeks after immunization with proquad.
għalhekk, jekk għandu jsir test tat- tuberkulina, dan għandu jingħata jew f' xi ħin qabel, fl- istess ħin ta ', jew għallinqas 4 sa 6 ġimgħat wara t- tilqima bi proquad.

there is also convincing evidence that uman big, along with active anti-hbv immunization, prevented transmission of hbv to newborns from anti- hbe+ mothers.
jeżistu wkoll provi konvinċenti li uman big, flimkien ma 'tilqim attiv kontra l- hbv, ipprevjena t- trasmissjoni tal- hbv lit- trabi tat- twelid minn omm anti- hbe+.

in an uncontrolled, open-label phase 3 study a single 6 mcg (0.5 ml) booster dose of ixiaro was given at month 15 after primary immunization.
fi studju mhux ikkontrollat, open-label, f’fażi 3, doża waħda booster ta’ 6 mcg (0.5 ml) ta’ ixiaro ġiet mogħtija fix-xahar 15 wara l-immunizzazzjoni primarja.